[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643166":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":50,"collaborators":23,"id":52,"slug":23,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":23,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":74,"whyStopped":23,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-6400 (Treatment Group A)","EXPERIMENTAL","Participants will be administered multiple doses of ALN-6400.",[13],"Drug: ALN-6400",{"label":15,"type":10,"description":11,"interventionNames":16},"ALN-6400 (Treatment Group B)",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","ALN-6400","ALN-6400 will be administered subcutaneously (SC).",[9,15],null,[25],{"name":26,"affiliation":5,"role":27},"Medical Director","STUDY_DIRECTOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":30,"role":31,"phone":35,"phoneExt":23,"email":33},"1-877-256-9526",[37],{"facility":38,"status":23,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":23},"Clinical Trial Site","Miami","Florida","33024","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-80.19366,25.77427,{"lat":48,"lon":47},{"type":51,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100643166",false,"NCT07575308","HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB","HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)","HMBeacon","Inclusion Criteria -\n\n* Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and platelet-type VWD) and HMB for 2 cycles during screening\n\nExclusion Criteria -\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the upper limit of normal (ULN)\n* Has total bilirubin greater than 1.5×ULN (except for patients with Gilbert's syndrome)\n* Has an estimated glomerular filtration (eGFR) less than 30 mL\u002Fmin\u002F1.73m\\^2 at screening\n* Is not willing to comply with the contraceptive requirements during the study period\n* Used routine factor prophylaxis (greater than or equal to 1 infusion of factor per week over 12 weeks) within 4 weeks of screening or plans use for routine factor prophylaxis during the study\n* New placement of any hormonal or nonhormonal intrauterine device (IUD) or hormonal implants within 24 weeks of screening\n* Known current gynecological conditions causing abnormal uterine bleeding (including infection, fibroids, endometriosis, polycystic ovary syndrome, or dysplasia)\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","FEMALE","16 Years","45 Years",{"count":63,"type":64},24,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB",[70,71],"Von Willebrand Disease (VWD)","Heavy Menstrual Bleeding (HMB)",[73],"siRNA, RNAi therapeutic, Plasminogen, PLG, VWD, HMB","NOT_YET_RECRUITING","2026-06-11",{"date":77,"type":78},"2026-06-15","ACTUAL",{"date":80,"type":64},"2026-06-30",{"date":82,"type":64},"2028-11-29",{"name":5,"class":6},1]